文献速递妇科肿瘤

基于肿瘤内在化疗敏感性(KELIM)识别一线治疗中获益最大的卵巢癌患者:GOG-0218验证研究

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
PubMed 文献 · J Clin Oncol · 2022-10-17

在GOG-0218试验中,对1,873例接受卡铂-紫杉醇±贝伐珠单抗/安慰剂治疗的高级别卵巢癌患者计算KELIM评分,1,662例可评估。KELIM不利组从贝伐珠单抗中获得PFS和OS获益,而KELIM有利组未获益;高风险且KELIM不利者获益最大。该研究验证了ICON-7的发现。

要点

  • KELIM不利(<1.0)组贝伐珠单抗较安慰剂PFS HR 0.70(95%CI 0.59-0.82),OS HR 0.87(95%CI 0.73-1.03)。
  • KELIM有利(≥1.0)组贝伐珠单抗无获益:PFS HR 0.96(95%CI 0.79-1.17),OS HR 1.11(95%CI 0.89-1.39)。
  • 高风险且KELIM不利者获益最大:PFS中位9.1 vs 5.6个月(HR 0.64),OS中位35.1 vs 29.1个月(HR 0.79)。

核心结论

  • GOG-0218试验验证了ICON-7的发现:肿瘤化疗敏感性差与同步-维持贝伐珠单抗获益相关。
  • 作者认为贝伐珠单抗可能主要对化疗敏感性差的患者有效。
  • 作者建议在高风险且化疗敏感性差的患者中优先考虑贝伐珠单抗以改善PFS/OS。

研究设计与样本

  • GOG-0218试验的external validation研究。
  • 1,873例患者接受卡铂-紫杉醇±同步-维持贝伐珠单抗/安慰剂治疗。
  • KELIM值由里昂大学团队根据前100天化疗期间的CA-125动力学计算。
  • NGR-GOG采用单因素/多因素分析独立评估KELIM评分与贝伐珠单抗获益的关联。
  • 1,662例有≥3个可用CA-125值的患者可评估KELIM。

主要发现

  • KELIM不利组贝伐珠单抗较安慰剂PFS HR 0.70(95%CI 0.59-0.82),OS HR 0.87(95%CI 0.73-1.03)。
  • KELIM有利组贝伐珠单抗较安慰剂PFS HR 0.96(95%CI 0.79-1.17),OS HR 1.11(95%CI 0.89-1.39)。
  • 高风险且KELIM不利者贝伐珠单抗较安慰剂PFS中位9.1 vs 5.6个月(HR 0.64,95%CI 0.53-0.78)。
  • 高风险且KELIM不利者贝伐珠单抗较安慰剂OS中位35.1 vs 29.1个月(HR 0.79,95%CI 0.65-0.97)。

关键数值与推荐

  • KELIM有利定义为≥1.0,不利定义为<1.0。
  • ICON-7中高风险疾病(减瘤不理想的III期或IV期)且KELIM<1.0者贝伐珠单抗OS获益:中位29.7 vs 20.6个月,HR 0.78。

临床怎么用

  • 作者建议在高风险且化疗敏感性差(KELIM<1.0)的患者中优先考虑贝伐珠单抗以改善PFS/OS。
  • 患者KELIM评分计算器可在Biomarker Kinetics网站获取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker. Only the patients with high-risk disease (suboptimally resected stage III, or stage IV) exhibiting unfavorable KELIM score < 1.0 had overall survival (OS) benefit from bevacizumab (median: 29.7 v 20.6 months; hazard ratio [HR], 0.78). An external validation study in the GOG-0218 trial was performed. METHODS: In GOG-0218, 1,873 patients were treated with carboplatin-paclitaxel ± concurrent-maintenance bevacizumab/placebo. Patient KELIM values were calculated with CA-125 kinetics during the first 100 chemotherapy days by the Lyon University team. The association between KELIM score (favorable ≥ 1.0, or unfavorable < 1.0) and bevacizumab benefit for progression-free survival (PFS)/OS was independently assessed by NGR-GOG using univariate/multivariate analyses. RESULTS: KELIM was assessable in 1,662 patients with ≥ 3 CA-125 available values. An unfavorable KELIM score was associated with bevacizumab benefit compared with placebo (PFS: HR, 0.70; 95% CI, 0.59 to 0.82; OS: HR, 0.87; 95% CI, 0.73 to 1.03), whereas a favorable KELIM was not (PFS: HR, 0.96; 95% CI, 0.79 to 1.17; OS: HR, 1.11; 95% CI, 0.89 to 1.39). The highest benefit was observed in patients with a high-risk disease exhibiting unfavorable KELIM, for PFS (median: 9.1 v 5.6 months; HR, 0.64; 95% CI, 0.53 to 0.78), and for OS (median: 35.1 v 29.1 months; HR, 0.79; 95% CI, 0.65 to 0.97). CONCLUSION: This GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritized in patients with a high-risk and poorly chemosensitive disease to improve their PFS/OS (patient KELIM score calculator available on the Biomarker Kinetics website).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. You B, Purdy C, Copeland LJ, et al. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022. PMID: 36252167. doi:10.1200/JCO.22.01207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。